4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605491054 | ||
| 003 | CHVBK | ||
| 005 | 20210128100508.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150601xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0731-1 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0731-1 | ||
| 245 | 0 | 0 | |a 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study |h [Elektronische Daten] |c [Naoto Takase, Koji Matsumoto, Takuma Onoe, Akihito Kitao, Maki Tanioka, Yoshitaka Kikukawa, Satoshi Yamaguchi, Kiyoshi Fujiwara, Shunichi Negoro] |
| 520 | 3 | |a Background: Platinum agents are essential for treating gynecological malignancies, particularly ovarian cancer. However, multiple carboplatin doses may cause hypersensitivity reactions (HSRs). Carboplatin desensitization prevents life-threatening HSRs and promotes the successful completion of planned chemotherapy. Methods: Since January 2010, carboplatin desensitization was performed at our institution. Solutions with 1/1000, 1/100, and 1/10 dilutions of carboplatin and an undiluted solution were prepared in 250mL of 5% glucose. Each solution was administered as a 1-h intravenous infusion (4-step 4-h protocol). This retrospective analysis was approved by the institutional review board. Results: From January 2010 to December 2013, 20 patients with gynecological malignancies (median age 62years, range 43-74years) received desensitization treatment. The International Federation of Gynecology and Obstetrics stages at presentation were I, II, III, and IV in 1, 1, 15, 13 patients, respectively. During first-line and second-line treatments, 3 and 17 patients, respectively, experienced carboplatin-induced HSRs. The median carboplatin cycle number was 11 (range 2-16). In the first desensitization cycle, 17 (85%) patients completed treatment without adverse events, 2 experienced Grade 1 HSRs but completed treatment, and 1 experienced Grade 3 HSR and discontinued treatment. The first desensitization cycle completion rate was 95%. Of 83 desensitization cycles administered, 79 (95.2%) were completed. No treatment-related deaths occurred. Conclusions: Most patients completed the planned chemotherapy. Our protocol could be conducted safely with shorter duration and simpler procedures than previous protocols. Carboplatin desensitization seems beneficial for patients with a history of carboplatin-induced HSRs; however, the risk of HSR recurrence still remains. Desensitization should therefore be performed only by well-trained staff. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Ovarian cancer |2 nationallicence | |
| 690 | 7 | |a Desensitization |2 nationallicence | |
| 690 | 7 | |a Carboplatin |2 nationallicence | |
| 690 | 7 | |a Hypersensitivity reaction |2 nationallicence | |
| 690 | 7 | |a Gynecological malignancy |2 nationallicence | |
| 700 | 1 | |a Takase |D Naoto |u Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan |4 aut | |
| 700 | 1 | |a Matsumoto |D Koji |u Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan |4 aut | |
| 700 | 1 | |a Onoe |D Takuma |u Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan |4 aut | |
| 700 | 1 | |a Kitao |D Akihito |u Department of General Medicine, Public Toyooka Hospital, 1094 Tobera, 668-8501, Toyooka, Hyogo, Japan |4 aut | |
| 700 | 1 | |a Tanioka |D Maki |u Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan |4 aut | |
| 700 | 1 | |a Kikukawa |D Yoshitaka |u Department of Hematology, Kumamoto University School of Medicine, 860-8556, Kumamoto, Japan |4 aut | |
| 700 | 1 | |a Yamaguchi |D Satoshi |u Department of Gynecology, Hyogo Cancer Center, 673-8558, Akashi, Hyogo, Japan |4 aut | |
| 700 | 1 | |a Fujiwara |D Kiyoshi |u Department of Gynecology, Hyogo Cancer Center, 673-8558, Akashi, Hyogo, Japan |4 aut | |
| 700 | 1 | |a Negoro |D Shunichi |u Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 566-573 |x 1341-9625 |q 20:3<566 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0731-1 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0731-1 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Takase |D Naoto |u Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Matsumoto |D Koji |u Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Onoe |D Takuma |u Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kitao |D Akihito |u Department of General Medicine, Public Toyooka Hospital, 1094 Tobera, 668-8501, Toyooka, Hyogo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tanioka |D Maki |u Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kikukawa |D Yoshitaka |u Department of Hematology, Kumamoto University School of Medicine, 860-8556, Kumamoto, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yamaguchi |D Satoshi |u Department of Gynecology, Hyogo Cancer Center, 673-8558, Akashi, Hyogo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Fujiwara |D Kiyoshi |u Department of Gynecology, Hyogo Cancer Center, 673-8558, Akashi, Hyogo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Negoro |D Shunichi |u Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 566-573 |x 1341-9625 |q 20:3<566 |1 2015 |2 20 |o 10147 | ||